Compare Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033 (SLVO) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033 vs TransMedics Group Inc — how do they compare? Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033 trades at $65.1, while TransMedics Group Inc trades at $74.3 (market cap $2.54B). Which is the better fit depends on your goals.
| SLVO | TMDX | |
|---|---|---|
Sector | Income / Options Overlay | Technology |
52-Week High | $107.41 | $150.42 |
52-Week Low | $61.81 | $61.99 |
Market Cap | — | $2.54B |
Enterprise Value | — | $2.94B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SLVO trades at $62.98, up 0.99% on the day, but technical indicators signal a bearish trend with moving averages unanimously negative. Key financial ratios including P/E, P/S, and ROE are unavailable, limiting fundamental clarity. The stock faces resistance near $64 with support at $63, indicating tight trading boundaries amid weak momentum.
The outlook remains cautious due to bearish technicals and missing fundamental data. Risks include potential downside if support breaks, while any positive earnings or guidance could reverse sentiment. Investors require updated financial disclosures to assess valuation and growth prospects accurately.
TransMedics (TMDX) trades at $73.47, down 0.69% with neutral technical signals. The stock shows strong profitability with 27% net margins and 45% ROE, though Q1 2026 earnings missed expectations. Recent strategic investment in European aviation logistics aims to expand the Organ Care System platform. Analyst consensus remains bullish with a $108.71 price target representing 48% upside potential.
Long-term growth prospects appear solid given TMDX's expanding transplant ecosystem, but near-term margin pressure from expansion investments and execution risks warrant caution. The company maintains competitive advantages in organ transplant logistics, though increased spending and competitive threats from alternatives like Strata Critical Medical present headwinds for shareholder returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033
SLVO is an exchange-traded note issued by UBS AG that provides investors with exposure to the performance of a silver-based covered call strategy. The ETN tracks the daily return of the ISE Enhanced 100x Leveraged Silver ETN Index, which combines a long position in silver with a covered call strategy on the silver position. This strategy aims to generate current income from the option premiums, which can provide a buffer during sideways or slightly down markets for silver, but it also caps the potential gains from a significant rise in silver prices. As an ETN, it is subject to the credit risk of the issuer, UBS AG, and has an expiration date of April 21, 2033.
Read more on SLVO →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
